|
NBPF3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.60139999985753E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.839499999574E-07 |
| Normal-vs-Stage2 |
4.015900E-04 |
| Normal-vs-Stage3 |
5.75980000028231E-07 |
| Normal-vs-Stage4 |
3.26960000185395E-08 |
| Stage1-vs-Stage2 |
3.946800E-01 |
| Stage1-vs-Stage3 |
6.242400E-01 |
| Stage1-vs-Stage4 |
1.359360E-01 |
| Stage2-vs-Stage3 |
6.667400E-01 |
| Stage2-vs-Stage4 |
7.267500E-02 |
| Stage3-vs-Stage4 |
9.212200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.15400000455912E-08 |
| Normal-vs-AfricanAmerican |
2.336000E-01 |
| Normal-vs-Asian |
3.36599999994913E-06 |
| Caucasian-vs-AfricanAmerican |
1.129510E-02 |
| Caucasian-vs-Asian |
7.518600E-01 |
| AfricanAmerican-vs-Asian |
1.040150E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.97649999489747E-08 |
| Normal-vs-Female |
2.70620004183542E-09 |
| Male-vs-Female |
1.362550E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.2651999997958E-07 |
| Normal-vs-Age(41-60Yrs) |
3.9705999999029E-07 |
| Normal-vs-Age(61-80Yrs) |
4.28120000000032E-05 |
| Normal-vs-Age(81-100Yrs) |
1.593780E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.566800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.507550E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.496200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.196800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.699000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.656800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.460200E-03 |
| Classical-VS-Follicular |
6.072300E-02 |
| Classical-VS-Other |
3.195200E-01 |
| Classical-VS-Normal |
5.46360000019952E-07 |
| Tall-VS-Follicular |
2.797900E-04 |
| Tall-VS-Other |
9.128200E-01 |
| Tall-VS-Normal |
1.73180003670836E-09 |
| Follicular-VS-Other |
1.617770E-01 |
| Follicular-VS-Normal |
3.816300E-04 |
| Other-VS-Normal |
6.095300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.83160000000182E-06 |
| Normal-vs-N1 |
3.56469964657435E-10 |
| N0-vs-N1 |
5.74019999999287E-05 |
|
|
